$2.67
+0.13 (+5.12%)
Open$2.55
Previous Close$2.54
Day High$2.68
Day Low$2.54
52W High$10.00
52W Low$2.13
Volume—
Avg Volume147.9K
Market Cap38.33M
P/E Ratio—
EPS$-3.21
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,251.3% upside
Current
$2.67
$2.67
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.69M | 8.74M | 8.70M |
| Net Income | -45,002,431 | -76,794 | -87,592 |
| Profit Margin | -673.1% | -0.9% | -1.0% |
| EBITDA | -47,220,563 | -105,264 | -93,337 |
| Free Cash Flow | — | -51,137 | -57,721 |
| Rev Growth | — | +8.7% | -7.3% |
| Debt/Equity | — | 0.73 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |